South Korean pharmaceutical firm Celltrion said on Tuesday that in an attempt to offset the risk of U.S. tariffs it had ...

South Korean pharmaceutical giant Celltrion announced on Tuesday that it has emerged as the preferred bidder to acquire a U.S ...

Celltrion Group Chairman and founder Seo Jung-jin said Tuesday that the company is preparing for new US tariffs by moving ...

Among high achievers are biopharmaceutical contract manufacturers in South Korea -- Samsung Biologics and Celltrion, both ...

Daewoong Pharmaceutical said Tuesday that it has decided to launch a biosimilar business as the Korean traditional drug maker ...

Celltrion and its biosimilar marketing partner Teva may be on their way to challenging Roche’s top drug, Rituxan. On Wednesday, independent FDA advisers unanimously signed off on Celltrion’s ...

Celltrion, a South Korean biopharma, said that despite receiving Complete Response Letters from the FDA, it remains optimistic it will get U.S. approval for its two biosimilar drugs, Rituxan and ...

TORONTO, March 27, 2025--Celltrion, Inc., a leading global biopharmaceutical company, announced that Remdantry™ will be available in Canada as of April 1, 2025. Remdantry™, previously known as ...

Celltrion’s representative anticancer drugs, Truxima (ingredient name rituximab) and Herjuma (ingredient name trastuzumab), also boast nearly 30% market share in Europe.

Celltrion began a recall of the 162,000 tests sold in the U.S. back in December when it said it had sent cease-and-desist letters to all distributors who had illegally sold the kits without the ...

Three is turning out to be a not-so-magical number for Celltrion, which this week racked up a third Class I tag in less than two months for yet another recall of its rapid antigen COVID-19 tests.

Celltrion Healthcare recently presented research from two studies conducted on its CT-P13 subcutaneous (SC) formulation (biosimilar infliximab) demonstrating positive results for the use of CT-P13 ...